CEL SCI CORP
CVMNYSEHealthcare · Biological Products, (No Diagnostic Substances) · CO · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$24.8M | −$26.4M | −$31.5M | −$36.1M | −$36.2M | −$29.0M |
| Net income | −$25.4M | −$26.9M | −$32.4M | −$36.7M | −$36.4M | −$30.3M |
| Total assets | $28.2M | $27.0M | $30.5M | $50.5M | $75.9M | $40.5M |
| Total liabilities | $12.2M | $14.1M | $17.3M | $18.4M | $19.3M | $20.8M |
| Equity | $16.0M | $12.9M | $13.2M | $32.2M | $56.5M | $19.7M |
| EPS (diluted) | $-6.27 | $-15.31 | $-0.73 | $-0.87 | $-0.90 | $-0.82 |
| Shares out. | 8.4M | 2.1M | 50.0M | 43.7M | 43.2M | 39.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −159.2%
- Return on assets
- −90.3%
- Return on capital (ROCE)
- −107.8%
- Liabilities / assets
- 43.3%
- Debt / equity
- 0.76×
- Book value / share
- $1.90
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -65.50distress
- Accruals / assets
- −29.4%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Dec 30, 2024
- NT 10-Kmissed a reporting deadline ↗Dec 15, 2016
- NT 10-Kmissed a reporting deadline ↗Dec 12, 2014
- NT 10-K/Amissed a reporting deadline ↗Dec 17, 2013
- NT 10-Kmissed a reporting deadline ↗Dec 17, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Lincoln Alternative Strategies LlcPassive (13G)Aug 29, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Kersten Geert ROfficer — Chief Executive Officer | May 14, 2026 | Buy | 300,000 | $1.20 |
| Kersten Geert ROfficer — Chief Executive Officer | May 13, 2026 | Buy | 100,000 | $1.19 |
| Talor EyalOfficer — Chief Scientific Officer | Mar 31, 2026 | Grant | 747 | $3.21 |
| Prichep Patricia BOfficer — Chief Financial Officer | Mar 31, 2026 | Grant | 1,336 | $3.21 |
| Kersten Geert ROfficer — Chief Executive Officer | Mar 31, 2026 | Grant | 1,682 | $3.21 |
| Kersten Geert ROfficer — Chief Executive Officer | Jan 22, 2026 | Buy | 38,023 | $5.26 |
| Talor EyalOfficer — Chief Scientific Officer | Dec 31, 2025 | Grant | 456 | $5.26 |
| Prichep Patricia BOfficer — Chief Financial Officer | Dec 31, 2025 | Grant | 815 | $5.26 |
| Kersten Geert ROfficer — Chief Executive Officer | Dec 31, 2025 | Grant | 998 | $5.26 |
| Kersten Geert ROfficer — Chief Executive Officer | Dec 4, 2025 | Buy | 8,389 | $5.96 |
| Talor EyalOfficer — Chief Scientific Officer | Sep 30, 2025 | Grant | 260 | $9.20 |
| Prichep Patricia BOfficer — Chief Financial Officer | Sep 30, 2025 | Grant | 466 | $9.20 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 255,031 | 1.0 | -64.0% |
| Apr 30, 2026 | 708,414 | 8.1 | +50.1% |
| Apr 15, 2026 | 471,843 | 8.8 | +0.8% |
| Mar 31, 2026 | 468,191 | 14.1 | -5.5% |
| Mar 13, 2026 | 495,343 | 11.7 | -1.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreementMay 14, 2026
- Entered a material agreement · Other material eventMay 13, 2026
- Modified shareholder rightsNov 24, 2025
- Modified shareholder rightsNov 5, 2025
- Entered a material agreement · Other material eventAug 29, 2025
- Other material eventAug 25, 2025
- Entered a material agreement · Other material eventJul 14, 2025
- Entered a material agreement · Other material eventMay 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- RWFORM RWMay 27, 2026
- RWFORM RWMay 19, 2026
- 4PRIMARY DOCUMENTMay 18, 2026
- 10-QFORM 10-QMay 15, 2026
- 8-KFORM 8-KMay 14, 2026
- 4PRIMARY DOCUMENTMay 14, 2026
- 8-KFORM 8-KMay 13, 2026
- 424B4May 13, 2026
- EFFECTMay 11, 2026
- S-1/AFORM S-1/AMay 1, 2026
- DEL AMApr 24, 2026
- S-1FORM S-1Apr 17, 2026
- 4PRIMARY DOCUMENTApr 1, 2026
- 4PRIMARY DOCUMENTApr 1, 2026
- 4PRIMARY DOCUMENTApr 1, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.